News Information
Focusing on cutting-edge technology and conveying industry voices
The editor shares with you a groundbreaking achievement published in Nature Communications by the Southwest Hospital of the Third Military Medical University: TRACKer (Target-Responsive non‑preAmplification Cell‑free diagnostic Kit), a low‑cost, scalable solution. Leveraging cell‑free protein synthesis (CFPS) technology, the research team has streamlined the entire assay workflow to just 70 minutes (the CFPS kit was supplied by Suzhou Perotin Biotechnology Co., Ltd.).
2026/05/28
To establish a platform for research collaboration between universities and enterprises, disseminate cutting-edge biotechnological innovations, and support the advancement of research and education in synthetic biology and biopharmaceuticals, on May 25, Perotin Bio, in partnership with the Kasma Platform, visited the Southern University of Science and Technology to jointly foster campus‑based scientific innovation.
2026/05/26
Recently, Dr. Li Xiaobo, Deputy General Manager of Suzhou Perotin Biotechnology Co., Ltd. (hereinafter referred to as “Perotin Bio”), along with his delegation, paid an in-depth visit to Shuimu Future—world’s largest specialized electron microscopy service company, backed by investment from Tsinghua University—and engaged in fruitful technical exchanges.
2026/05/21
The official website of Suzhou Perotin Biotechnology Co., Ltd. has been completely revamped and officially launched.
2026/05/21
Recently, Dr. Li Xiaobo, Chief Marketing Advisor at Perotin Bio, was invited to visit the Institute of Materia Medica, Chinese Academy of Medical Sciences, where he delivered a specialized academic lecture on cell-free protein expression technology. A large number of researchers from the institute attended and participated in the session.
2026/04/27
The Future of Biopharma is Cell-Free: Partner with PLD Technology to Lead the Frontier
The winds of change are here, and the science-and-tech sector is ripe with opportunity. PLD Technology is a global pioneer in Cell-Free Protein Synthesis (CFPS) technology. By leveraging groundbreaking foundational innovations, we are disrupting industry barriers and capturing market leadership with premium, high-performance products.
2026/04/23
From March 31 to April 1, 2026, the Fifth China Synthetic Biology and Biomanufacturing Conference will be held at the Hangzhou Heda DoubleTree by Hilton Hotel. This conference will feature Dr. Cui Jinhui, CEO of Suzhou Perotin Biotechnology Co., Ltd., who will deliver a keynote presentation titled “A Cell-Free Protein Expression Platform: Empowering Efficient Front-End R&D in Biomanufacturing Processes.” As a leading company in cell-free protein expression technology, Perotin Biotechnology will also exhibit at the Fifth China Synthetic Biology and Biomanufacturing Conference (Booth No. A10). We warmly invite both new and existing customers to visit our booth.
2026/03/19
Highlights | The Perotin Yimao Trade Fair Concludes Successfully!
On March 14, 2026, the 11th Yimao Bio‑Industry Exhibition (BIOCHINA 2026) successfully concluded at the Suzhou International Expo Center. As the annual highlight of the biopharmaceutical sector, this year’s event was themed “Integration & Leadership,” bringing together over 30,000 industry professionals from more than 40 countries and regions to discuss the latest trends and future directions of the biopharmaceutical industry. PLD Technology was invited to participate in interviews and showcased its products with great distinction, presenting its core cell‑free protein expression solutions and fully demonstrating its innovative strength at this premier industry gathering, reaping abundant recognition and opportunities.
2026/03/19
In the fields of metabolic engineering and synthetic biology, research efficiency has long been constrained by a persistent challenge: while design capabilities continue to improve, the pace of experimental validation consistently lags behind. With advances in computational design, automation, and AI technologies, researchers can now generate vast numbers of enzyme‑mutant and metabolic‑pathway design options in a short time. However, how to rapidly screen and validate these designs remains a critical bottleneck that limits progress in R&D.
2026/03/18
Contact Information
Service Hotline: +86-512-67900128
Customer Service: order@sz-pld.tech
Business Cooperation: bd@sz-pld.tech
Address: Room 302, Building 1, Weili Medical Science and Technology Park, No. 69 Jiepu Road, Suzhou Industrial Park
